Dendritic cells loaded with the lysate of tumor cells infected with Newcastle Disease Virus trigger potent anti‑tumor immunity by promoting the secretion of IFN‑γ and IL‑2 from T cells

Zhao,Lianjing; Niu,Chao; Shi,Xiumin; Xu,Dongsheng; Li,Min; Cui,Jiuwei; Li,Wei; Xu,Jianting; Jin,Haofan

doi:10.3892/ol.2018.8785

Dendritic cells loaded with the lysate of tumor cells infected with Newcastle Disease Virus trigger potent anti‑tumor immunity by promoting the secretion of IFN‑γ and IL‑2 from T cells

Authors:
- Lianjing Zhao
- Chao Niu
- Xiumin Shi
- Dongsheng Xu
- Min Li
- Jiuwei Cui
- Wei Li
- Jianting Xu
- Haofan Jin
View Affiliations

Affiliations: Cancer Center, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: May 22, 2018 https://doi.org/10.3892/ol.2018.8785
Pages: 1180-1188

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Dendritic cells (DCs) are professional antigen‑presenting cells that are pivotal in the generation and sustainability of antitumor immune responses. Whole tumor cell lysates (TCLs) have been used as sources of tumor antigens for the development of DC vaccines. However, the clinical outcomes of the use of TCL‑based DC vaccines have so far been unsatisfactory because of the weak immunogenicity of tumor cells. To improve the efficacy of TCL‑based DC vaccines, viruses have been used to enhance the immunity of TCLs and to further enhance the antigen delivery and antigen‑presenting ability of DCs. The aim of the present study was to improve the antigen‑presenting ability of DCs and to use them to effectively activate T lymphocytes. The present study demonstrated that DCs loaded with the lysate of Newcastle Disease Virus (NDV)‑infected tumor cells (NDV‑TCL) have increased levels of cluster of differentiation 80 (CD80), CD86, CD83 and human leukocyte antigen‑antigen D‑associated expression, compared with those loaded with TCL alone. The DCs loaded with the NDV‑TCL promoted T‑cell proliferation and antitumor cytokine secretion from T cells. These results indicated that loading DCs with NDV‑TCL could enhance the antigen‑presenting ability of the DCs. On the basis of the results of the present study, we hypothesize that this method of loading DCs with NDV‑TCL can be used to develop novel DC vaccines for tumor immunotherapy in the future.

View Figures

View References

1	Sehgal K, Dhodapkar KM and Dhodapkar MV: Targeting human dendritic cells in situ to improve vaccines. Immunol Lett. 162:59–67. 2014. View Article : Google Scholar : PubMed/NCBI
2	Steinman RM: Some interfaces of dendritic cell biology. APMIS. 111:675–697. 2003. View Article : Google Scholar : PubMed/NCBI
3	Andrews DM, Scalzo AA, Yokoyama WM, Smyth MJ and Degli-Esposti MA: Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol. 4:175–181. 2003. View Article : Google Scholar : PubMed/NCBI
4	Schirrmacher V, Ahlert T, Pröbstle T and Steiner HH, Herold-Mende C, Gerhards R, Hagmüller E and Steiner HH: Immunization with virus-modified tumor cells. Semin Oncol. 25:677–696. 1998.PubMed/NCBI
5	Thara E, Dorff TB, Pinski JK and Quinn DI: Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas. 69:296–303. 2011. View Article : Google Scholar : PubMed/NCBI
6	Cohn L and Delamarre L: Dendritic cell-targeted vaccines. Front Immunol. 5:2552014. View Article : Google Scholar : PubMed/NCBI
7	Guillerme JB, Boisgerault N, Roulois D, Ménager J, Combredet C, Tangy F, Fonteneau JF and Gregoire M: Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells. Clin Cancer Res. 19:1147–1158. 2013. View Article : Google Scholar : PubMed/NCBI
8	Maamary J, Array F, Gao Q, García-Sastre A, Steinman RM, Palese P and Nchinda G: Newcastle disease virus expressing a dendritic cell-targeted HIV gag protein induces a potent gag-specific immune response in mice. J Virol. 85:2235–2246. 2011. View Article : Google Scholar : PubMed/NCBI
9	Fournier P and Schirrmacher V: Oncolytic Newcastle Disease Virus as cutting edge between tumor and host. Biology (Basel). 2:936–975. 2013.PubMed/NCBI
10	Melchjorsen J, Jensen SB, Malmgaard L, Rasmussen SB, Weber F, Bowie AG, Matikainen S and Paludan SR: Activation of innate defense against a paramyxovirus is mediated by RIG-I and TLR7 and TLR8 in a cell-type-specific manner. J Virol. 79:12944–12951. 2005. View Article : Google Scholar : PubMed/NCBI
11	Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, Matsui K, Tsujimura T, Takeda K, Fujita T, Takeuchi O and Akira S: Cell type-specific involvement of RIG-I in antiviral response. Immunity. 23:19–28. 2005. View Article : Google Scholar : PubMed/NCBI
12	Fournier P, Arnold A and Schirrmacher V: Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus. J BUON. 14(Suppl 1): S111–S122. 2009.PubMed/NCBI
13	Austin FC and Boone CW: Virus augmentation of the antigenicity of tumor cell extracts. Adv Cancer Res. 30:301–345. 1979. View Article : Google Scholar : PubMed/NCBI
14	Sinkovics JG and Horvath JC: Virus therapy of human cancers. Melanoma Res. 13:431–432. 2003. View Article : Google Scholar : PubMed/NCBI
15	Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
16	Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, et al: Expression of programmed death 1 ligands by murine T cells and APC. J Immunol. 169:5538–5545. 2002. View Article : Google Scholar : PubMed/NCBI
17	Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, Greenfield EA and Freeman GJ: Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 170:1257–1266. 2003. View Article : Google Scholar : PubMed/NCBI
18	Nguyen LT and Ohashi PS: Clinical blockade of PD1 and LAG3 - potential mechanisms of action. Nat Rev Immunol. 15:45–56. 2015. View Article : Google Scholar : PubMed/NCBI
19	Williams EH, Williams CA and McLeod JD: Identification of PDL-1 as a novel biomarker of sensitizer exposure in dendritic-like cells. Toxicol In Vitro. 24:1727–1735. 2010. View Article : Google Scholar : PubMed/NCBI
20	Kalinski P, Edington H, Zeh HJ, Okada H, Butterfield LH, Kirkwood JM and Bartlett DL: Dendritic cells in cancer immunotherapy: Vaccines or autologous transplants? Immunol Res. 50:235–247. 2011. View Article : Google Scholar : PubMed/NCBI
21	Gao F, Liu C, Guo J, Sun W, Xian L, Bai D, Liu H, Cheng Y, Li B, Cui J, et al: Radiation-driven lipid accumulation and dendritic cell dysfunction in cancer. Sci Rep. 5:96132015. View Article : Google Scholar : PubMed/NCBI
22	Reichardt P, Dornbach B and Gunzer M: APC, T cells, and the immune synapse. Curr Top Microbiol Immunol. 340:229–249. 2010.PubMed/NCBI
23	Linette GP and Carreno BM: Dendritic cell-based vaccines: Shining the spotlight on signal 3. Oncoimmunology. 2:e265122013. View Article : Google Scholar : PubMed/NCBI
24	Talay O, Shen CH, Chen L and Chen J: B7-H1 (PD-L1) on T cells is required for T-cell-mediated conditioning of dendritic cell maturation. Proc Natl Acad Sci USA. 106:2741–2746. 2009. View Article : Google Scholar : PubMed/NCBI
25	Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ and Sharpe AH: Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 33:2706–2716. 2003. View Article : Google Scholar : PubMed/NCBI
26	Rodig N, Ryan T, Allen JA, Pang H, Grabie N, Chernova T, Greenfield EA, Liang SC, Sharpe AH, Lichtman AH and Freeman GJ: Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis. Eur J Immunol. 33:3117–3126. 2003. View Article : Google Scholar : PubMed/NCBI
27	Goto T, Nishida T, Takagi E, Miyao K, Koyama D, Sakemura R, Hanajiri R, Watanabe K, Imahashi N, Terakura S, et al: Programmed death-ligand 1 on antigen-presenting cells facilitates the induction of antigen-specific cytotoxic T lymphocytes: Application to adoptive T-cell immunotherapy. J Immunother. 39:306–315. 2016. View Article : Google Scholar : PubMed/NCBI
28	Martin-Orozco N, Wang YH, Yagita H and Dong C: Cutting Edge: Programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens. J Immunol. 177:8291–8295. 2006. View Article : Google Scholar : PubMed/NCBI
29	Okazaki T and Honjo T: The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 27:195–201. 2006. View Article : Google Scholar : PubMed/NCBI
30	Millán O, Rafael-Valdivia L, Torrademé E, López A, Fortuna V, Sánchez-Cabus S, López-Púa Y, Rimola A and Brunet M: Intracellular IFN-gamma and IL-2 expression monitoring as surrogate markers of the risk of acute rejection and personal drug response in de novo liver transplant recipients. Cytokine. 61:556–564. 2013. View Article : Google Scholar : PubMed/NCBI
31	Shimoda M, Tomimaru Y, Charpentier KP, Safran H, Carlson RI and Wands J: Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma. J Hepatol. 56:1129–1135. 2012. View Article : Google Scholar : PubMed/NCBI